UpToDate
Article
UpToDate is a recurring publication in the Astral Codex Ten archive, appearing 5 times across 5 issues between February 22, 2021 and January 24, 2022. The archive places it in contexts such as “no major academic or popular resource (eg UpToDate, NICE, Wikipedia, WebMD)”; “According to UpToDate ($) “CBT for insomnia (CBT-I) is preferred as first-line therapy for chronic insomnia in most patients.""; “UpToDate says that: In four randomized trials”. It most often appears alongside FDA, NICE, Substack.
Metadata
- Category: Publications
- Mention count: 5
- Issue count: 5
- First seen: February 22, 2021
- Last seen: January 24, 2022
Appears In
- A Look Down Track B
- Highlights From The Comments On CBT-i Apps
- Peer Review Request: Ketamine
- Details Of The Infant Fish Oil Story
- Grading My 2021 Predictions
Related Pages
-
- FDA (4 shared issues)
-
- NICE (2 shared issues)
-
- Substack (2 shared issues)
-
- US (2 shared issues)
-
- 538 (1 shared issues)
-
- ACX (1 shared issues)
-
- Adderall (1 shared issues)
-
- alcohol (1 shared issues)
-
- American College of Clinical Pharmacy (1 shared issues)
-
- AMPA receptors (1 shared issues)
-
- amphetamine (1 shared issues)
External Links
Source Context
Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.
...but I look forward to seeing further attempts to replicate and explicate these interesting results. Prediction: 90% chance that no major academic or popular resource (eg UpToDate, NICE, Wikipedia, WebMD) will give this theory prominence equal to or greater than the standard serotonin theory in its explanation of antidepressant effects by 2030, un...
...F -> TrkB -> nerve growth theory for now, but I look forward to seeing further attempts to replicate and explicate these interesting results. Prediction: 90% chance that no major academic or popular resource (eg UpToDate, NICE, Wikipedia, WebMD) will give this theory prominence equal to or greater than the standard serotonin theory in its explanation of antidepressant effects by 2030, unless this is because some...
According to UpToDate ($) "CBT for insomnia (CBT-I) is preferred as first-line therapy for chronic insomnia in most patients. Several prospective studies have assessed the comparative efficacy of CBT-I, medications, and combination therapy as an initial approach. In short-term trials, CBT-I alone and CBT-I in combination with medications demonstrate relatively equivalent outcomes, and both are superior to medication alone."
Inline links: UpToDate
Psychiatric doses of ketamine do cause transient hypertension, pretty often. UpToDate says that:
The standard dose of IV ketamine is 0.5 mg/kg (eg 35 mg for a 70 kg person). This is the dose used in most studies and recommended by UpToDate. If that doesn’t work, some people will try going up to 1 mg/kg.
Inline links: most studies
The standard dose of intranasal ketamine is 50 – 80 mg. This is more or less the dose recommended by UpToDate, the dose used in most studies, the FDA-recommended dose of Spravato, and the dose that most successful ketamine providers have told me they use.
Inline links: most studies
UpToDate, the US gold standard medical evidence aggregator, says:
Inline links: says
COVID 23. Fewer than 10K daily average official COVID cases in US in December 2021: 30% 24. Fewer than 50K daily average COVID cases worldwide in December 2021: 1% 25. Greater than 66% of US population vaccinated against COVID: 50% 26. India's official case count is higher than US: 50% 27. Vitamin D is not generally recognized (eg NICE, UpToDate) as effective COVID treatment: 70% 28. Something else not currently used becomes first-line treatment for COVID: 40% 29. Some new variant not currently known is greater than 25% of cases: 50% 30. Some new variant where no existing vaccine is more than 50% effective: 40% 31. US approves AstraZeneca vaccine: 20% 32. Most people I see in the local grocery store aren't wearing a mask: 60%